Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry

Nodular melanoma (NM) is associated with a higher locoregional and distant recurrence rate compared with superficial spreading melanoma (SSM); it is unknown whether the efficacy of systemic therapy is limited. Here, we compare the efficacy of immunotherapy and BRAF/MEK inhibitors (BRAF/MEKi) in adva...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-11, Vol.14 (22), p.5694
Main Authors: Rauwerdink, Daan Jan Willem, van Doorn, Remco, van der Hage, Jos, Van den Eertwegh, Alfonsus J M, Haanen, John B A G, Aarts, Maureen, Berkmortel, Franchette, Blank, Christian U, Boers-Sonderen, Marye J, De Groot, Jan Willem B, Hospers, Geke A P, de Meza, Melissa, Piersma, Djura, Van Rijn, Rozemarijn S, Stevense, Marion, Van der Veldt, Astrid, Vreugdenhil, Gerard, Wouters, Michel W J M, Suijkerbuijk, Karijn, van der Kooij, Monique, Kapiteijn, Ellen
Format: Article
Language:English
Subjects:
CTLA-4 protein
Diagnosis
Immunotherapy
Invasiveness
MEK inhibitors
Melanoma
Metastases
Metastasis
Mutation
Patients
PD-1 protein
Satellites
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nodular melanoma (NM) is associated with a higher locoregional and distant recurrence rate compared with superficial spreading melanoma (SSM); it is unknown whether the efficacy of systemic therapy is limited. Here, we compare the efficacy of immunotherapy and BRAF/MEK inhibitors (BRAF/MEKi) in advanced NM to SSM. Patients with advanced stage IIIc and stage IV NM and SSM treated with anti-CTLA-4 and/or anti-PD-1, or BRAF/MEKi in the first line, were included from the prospective Dutch Melanoma Treatment Registry. The primary objectives were distant metastasis-free survival (DMFS) and overall survival (OS). In total, 1086 NM and 2246 SSM patients were included. DMFS was significantly shorter for advanced NM patients at 1.9 years (CI 95% 0.7−4.2) compared with SSM patients at 3.1 years (CI 95% 1.3−6.2) (p < 0.01). Multivariate survival analysis for immunotherapy and BRAF/MEKi demonstrated a hazard ratio for immunotherapy of 1.0 (CI 95% 0.85−1.17) and BRAF/MEKi of 0.95 (CI 95% 0.81−1.11). A shorter DMFS for NM patients developing advanced disease compared with SSM patients was observed, while no difference was observed in the efficacy of systemic immunotherapy or BRAF/MEKi between NM and SSM patients. Our results suggests that the worse overall survival of NM is mainly driven by propensity of metastatic outgrowth of NM after primary diagnosis.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14225694